Literature DB >> 1684727

Determination of 2-chloro-2'-deoxyadenosine in human plasma.

J Liliemark1, B Pettersson, G Juliusson.   

Abstract

The first high performance liquid chromatographic method for determination of the plasma concentration of 2-chloro-2'-deoxyadenosine (CdA) in patients, which is significantly more sensitive than the previously used RIA method, is presented. CdA is a purine analogue with useful clinical activity against lymphoproliferative disorders and it has recently been found to be the single most active agent in the treatment of hairy cell leukaemia. Guaneran (6-nitroimidazol-6-thioguanine) was added to 1 mL plasma as the internal standard and CdA was extracted using ethyl acetate. A Perkin-Elmer C18, 3 mu, 8 cm column was used for the separation of CdA and the internal standard from endogenous compounds in the sample with a mixture of sodium phosphate buffer 10 mM, methanol and acetonitrile (85:10:5, pH = 3.0) as the mobile phase. The sensitivity of the method (1 nM) allows the determination of CdA in plasma 24 h after the administration of 0.14 mg/kg as a 2 h infusion.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1684727     DOI: 10.1002/bmc.1130050607

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  7 in total

Review 1.  The clinical pharmacokinetics of cladribine.

Authors:  J Liliemark
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies.

Authors:  S A Johnson
Journal:  Clin Pharmacokinet       Date:  2000-07       Impact factor: 6.447

3.  Interspecies differences in the kinetic properties of deoxycytidine kinase elucidate the poor utility of a phase I pharmacologically directed dose-escalation concept for 2-chloro-2'-deoxyadenosine.

Authors:  V Reichelová; G Juliusson; T Spasokoukotskaja; S Eriksson; J Liliemark
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  Protein binding of 2-chloro 2'-deoxyadenosine (cladribine) in healthy subjects and in patients with leukaemia.

Authors:  F Albertioni; L Herngren; G Juliusson; J Liliemark
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 5.  Clinical and toxicological aspects of the antineoplastic drug cladribine: a review.

Authors:  H J Guchelaar; D J Richel; M R Schaafsma
Journal:  Ann Hematol       Date:  1994-11       Impact factor: 3.673

6.  On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole.

Authors:  F Albertioni; G Juliusson; J Liliemark
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 7.  Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases.

Authors:  Tadeusz Robak; Anna Korycka; Ewa Lech-Maranda; Pawel Robak
Journal:  Molecules       Date:  2009-03-23       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.